Translating discoveries as novel biomarkers and interventions in ophthalmology

Abstract

[...]local routes of administration, such as intravitreal injection, to treat ocular diseases will likely remain standard-of-care for certain agents [1, 2]. [...]the complex nature of ocular tissue, which consists of a combination of cell types including both CNS neurons and ophthalmic-specific cells, means that therapies developed for ophthalmic conditions may need to consider potential effects on different components of the eye [1,2,3]. There is a growing appreciation of the value of these technologies as both markers of disease activity and measures of response to treatment, not just for ophthalmic disease but also disorders affecting other organ systems.